Primary Peritoneal Carcinoma Completed Phase 2 Trials for Carotuximab (DB06322)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01381861Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaTreatment